Skip to main content

Advertisement

SpringerLink
Log in

Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

A range of studies have analyzed prognostic factors in bladder cancer. However, prior cohorts have included heterogeneous pT classification at biopsy and others were derived from large, multi-institutional clinical trials over the span of many years. Our objective was to analyze prognostic factors in a recent radical cystectomy (RC) cohort at a single institution and evaluate outcomes based on current practice patterns. A retrospective analysis of overall survival (OS) was conducted on 180 RC patients with biopsy proven pT2 disease between 2007–2010. Increasing pT classification was a negative predictor of survival. pT was grouped into three categories with pT0/a/is/1/2a surviving longer than pT2b/3a/3b, and pT4 having the worst prognosis. Subclassifying pT2 and pT3 showed no statistically significant difference in survival. Lymphovascular invasion (LVI) and node positivity correlated with decreased OS. Patients treated with neoadjuvant chemotherapy (NAC) had a higher incidence of pT0, yet pN1+ was more common and NAC was not associated with improved OS. This investigation provides reference OS values for patients with pathologically diagnosed muscle-invasive bladder cancer based on current medical guidelines outside the context of a clinical trial. pT4 was the strongest negative predictor of survival, followed by pN1+, the group pT2b/3a/3b, and presence of LVI. NAC patients were noted to have a higher frequency of low pT classification, yet more frequent node positivity, suggesting that pT classification in NAC patients may not accurately reflect remaining tumor burden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Cancer Society (2010) Cancer Facts and Figures 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf . Accessed 3 January 2012

  2. National Cancer Institute (2010). Bladder Cancer Information. http://www.cancer.gov/cancertopics/types/bladder. Accessed 3 January 2012

  3. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  PubMed  CAS  Google Scholar 

  4. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249

    Article  PubMed  CAS  Google Scholar 

  5. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055

    PubMed  CAS  Google Scholar 

  6. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

  7. Canter D, Long C, Kutikov A, Plimack E et al (2011) Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 107:58–62

    Article  PubMed  Google Scholar 

  8. Edge SB, Byrd DR, Comptom CC (2010) American Joint Committee on Cancer. AJCC Cancer Staging Manual, Seventh Edition. Springer, New York, pp 497–502

    Google Scholar 

  9. Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185:72–78

    Article  PubMed  Google Scholar 

  10. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675

    PubMed  CAS  Google Scholar 

  11. Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690–696

    Article  PubMed  Google Scholar 

  12. Weight CJ, Garcia JA, Hansel DE et al (2009) Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer 115:792–799

    Article  PubMed  Google Scholar 

  13. Manoharan M, Katkoori D, Kishore TA et al (2009) Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed. BJU Int 104:1646–1649

    Article  PubMed  Google Scholar 

  14. Pollack A, Zagars GK, Cole CJ et al (1995) The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154:2059–2063

    Article  PubMed  CAS  Google Scholar 

  15. Honma I, Masumori N, Sato E et al (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64:744–748

    Article  PubMed  Google Scholar 

  16. Tilki D, Svatek RS, Karakiewicz PI et al (2010) pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol 184:470–474

    Article  PubMed  Google Scholar 

  17. Sonpavde G, Khan MM, Svatek RS et al (2011) Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol 185:1216–1221

    Article  PubMed  Google Scholar 

  18. Yu RJ, Stein JP, Cai J et al (2006) Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176:493–8

    Article  PubMed  Google Scholar 

  19. Boudreaux KJ Jr, Clark PE, Lowrance WT et al (2009) Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181:540–545

    Article  PubMed  Google Scholar 

  20. Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 184:888–894

    Article  PubMed  Google Scholar 

  21. Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31–35

    PubMed  CAS  Google Scholar 

  22. Ghoneim MA, El-Mekresh MM, Mokhtar AA et al (2000) A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int 85:811–816

    Article  PubMed  CAS  Google Scholar 

  23. Abdel-Latif M, Abol-Enein H, El-Baz M et al (2004) Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol 172:85–89

    Article  PubMed  Google Scholar 

  24. Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539

    Article  PubMed  Google Scholar 

  25. Quek ML, Stein JP, Nichols PW et al (2005) Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 174:103–106

    Article  PubMed  Google Scholar 

  26. Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412

    Article  PubMed  Google Scholar 

  27. Yang XJ, Lecksell K, Eptsein JI (1999) Can immunohistochemistry enhance the detection of micrometasasis in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol 112:649–653

    PubMed  CAS  Google Scholar 

  28. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540

    Article  Google Scholar 

  29. Sonpavde G, Goldman BH, Speights VO et al (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104–4019

    Article  PubMed  Google Scholar 

  30. Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425

    Article  PubMed  CAS  Google Scholar 

  31. Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934

    Article  Google Scholar 

  32. Sherif A, Holmberg L, Rintala E et al (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297–303

    Article  PubMed  CAS  Google Scholar 

  33. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205

    Article  Google Scholar 

  34. International Collaboration of Trialists (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177

    Article  Google Scholar 

Download references

Conflicts of interest statement

We declare that we have no conflict of interest.

Funding/financial disclosures

None

Author information

Authors and Affiliations

  1. Department of Pathology, The Ohio State University Medical Center, 410 W 10th Ave 401 Doan Hall, Columbus, OH, 43210, USA

    Amber M. D’Souza, Tahir Arif & Debra L. Zynger

  2. Department of Urology, The Ohio State University Medical Center, Columbus, OH, USA

    Kamal S. Pohar

  3. Department of Hematology, The Ohio State University Medical Center, Columbus, OH, USA

    Susan Geyer

Authors
  1. Amber M. D’Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamal S. Pohar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tahir Arif
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Debra L. Zynger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Debra L. Zynger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

D’Souza, A.M., Pohar, K.S., Arif, T. et al. Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy. Virchows Arch 461, 467–474 (2012). https://doi.org/10.1007/s00428-012-1249-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-012-1249-4

Keywords

Search

Navigation